NACD appoints IBM and PwC executives to board of directors

WASHINGTON - The National Association of Corporate Directors (NACD) announced Friday the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately.

Mantas currently serves on the boards of Biogen (NASDAQ:BIIB), where he chairs the compensation and management development committee, and International Flavors & Fragrances (NYSE:IFF), where he participates on the innovation and audit committees. He is also a Senior Advisor for NASDAQ and recently retired from his position at IBM.

"As directors, we face compounding geopolitical, generational and technological disruption in the companies and communities we serve," Mantas said in a statement from the press release. According to InvestingPro analysis, Biogen appears undervalued at current levels, with multiple ProTips highlighting its strong financial position and market performance. Subscribers can access the comprehensive Pro Research Report for deeper insights into the company’s fundamentals and growth prospects.

Bricker oversees 134,000 Assurance partners and staff across the PwC network. He previously served as PwC U.S. vice chair and Trust Solutions co-leader and held the position of chief accountant at the U.S. Securities and Exchange Commission. Bricker also serves on the board of the American Institute of Certified Professional Accountants and chairs the board of XBRL International.

Peter Gleason, president and CEO of NACD, stated that both leaders bring "exceptional insight and experience that reflect the dynamic needs of today’s boards."

NACD, which has operated for more than 47 years, describes itself as the leading member organization for corporate directors with a network of more than 24,000 members across more than 20 chapters.

The appointments were announced in a press release issued by the organization. For investors interested in tracking the performance of companies like Biogen and their leadership changes, InvestingPro offers extensive financial metrics, Fair Value calculations, and expert analysis across more than 1,400 US stocks.

In other recent news, Biogen has reported several significant developments. RBC Capital has adjusted its price target for Biogen, lowering it slightly to $217 while maintaining an Outperform rating, and expects the company to exceed consensus estimates in its upcoming earnings report with projected revenue of $2,493 million and earnings per share of $4.43. Additionally, Biogen, in collaboration with Eisai Co., Ltd., announced the availability of Leqembi Iqlik, a subcutaneous injection for Alzheimer’s disease patients in the U.S., following FDA approval in August 2025. The company has also received a Complete Response Letter from the FDA for its high-dose SMA drug, requiring updates to technical information but noting no deficiencies in clinical data. Furthermore, Biogen has entered into an agreement to acquire Alcyone Therapeutics for $85 million, focusing on the ThecaFlex DRx system for intrathecal delivery of medicines. Jefferies has initiated coverage on Biogen with a Buy rating and a $190 price target, citing low market expectations and potential for positive developments in 2026. These recent updates highlight Biogen’s active engagement in drug development and strategic acquisitions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.